Apixaban vs standard of care after TAVI

to investigate the clinical outcomes of the use of apixaban versus standard of care after successful TAVI. Standard of care: stratum I: Vit. K antagonists entire study and stratum 2: pts with no indication for oral anticoagulation were given antiplatelet treatment: aspirin and/or clopidogrel

investigator-initiated open-label superiority multicentre randomised trial

patients with successful TAVI

composite of death, MI, stroke, TIA, systemic embolism, intracardiac or bioprothesis thrombosis, deep vein thrombosis, pulmonary embolism, life-threatening, disabling or major bleeding over 1-year follow-up. Safety endpoint: major, disabling or life-threatening bleeding